Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy

09/01/2021 | 02:00am EDT

Astellas Pharma Inc. announced that it has voluntarily paused screening and dosing of additional participants in its ASPIRO clinical trial evaluating AT132 in patients with X-linked Myotubular Myopathy. This decision follows the reporting of a recent serious adverse event (SAE) in a study participant due to abnormal liver function tests (LFTs) observed in the weeks following dosing of the AT132 investigational gene therapy product at a lower dose (1.3x1014 vg/kg). Astellas voluntarily halted screening and dosing, reported the SAE to regulatory agencies, and is engaged in dialogue with regulators about this SAE. At this time, an Investigational New Drug (IND) clinical hold has not been issued. In the U.S., an IND clinical hold is an order issued by the U.S. Food and Drug Administration (FDA) to the sponsor of a clinical trial to delay a proposed clinical trial or suspend an ongoing clinical trial. If Astellas receives a clinical hold letter, it will review the content and determine next steps.


© S&P Capital IQ 2021
All news about ASTELLAS PHARMA INC.
10/13Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
AQ
10/12ASTELLAS PHARMA : and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV..
PU
10/12SEAGEN : Astellas Complete Enrollment in Cohort K of Study of Padcev, Keytruda Combination..
MT
10/12ASTELLAS PHARMA : Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combini..
BU
10/11ASTELLAS PHARMA : World's First Use of Environmentally Friendly Biomass-based Plastic for ..
PU
10/05PRESS RELEASE : iOmx Therapeutics raises EUR 65 million in Series B round
DJ
10/05PRESS RELEASE : MIG Fonds leads EUR65 million Series B financing of iOmx Therapeutics
DJ
10/04PRESS RELEASE : MIG sells portfolio company Hemovent to MicroPort
DJ
10/01ASTELLAS PHARMA : Juntendo University and Astellas Establish "Direct Reprogramming Regener..
PU
09/30ASTELLAS PHARMA : Corporate Strategic Plan 2021—dedicated to realization
PU
More news
Financials
Sales 2022 1 325 B 11 580 M 11 580 M
Net income 2022 194 B 1 700 M 1 700 M
Net cash 2022 478 B 4 174 M 4 174 M
P/E ratio 2022 18,9x
Yield 2022 2,50%
Capitalization 3 710 B 32 494 M 32 424 M
EV / Sales 2022 2,44x
EV / Sales 2023 2,07x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 2 002,00 JPY
Average target price 2 482,31 JPY
Spread / Average Target 24,0%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.25.60%32 494
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657